Few Worries As Modern Insulins Drive Novo’s China Growth
This article was originally published in PharmAsia News
Executive Summary
The possibility of slowing growth in China does not seem to be a concern for investors in Novo Nordisk, which reported a steady rise in its business in this key emerging market in the first quarter.